Clinical significance of systemic inflammation response index and platelet–lymphocyte ratio in patients with stage I-III gastric cancer

Table 2 Univariate and multivariate analyses for predicting the survival outcomes of the training cohort

Clinicopathologic factors	Univariate analysis			Multivariate analysis
	Exp(B)	95.0%CI of Exp(B)	P value	Exp(B)	95.0%CI of Exp(B)	P value
Sex	0.961	0.749-1.233	0.752
Age	1.431	1.157-1.770	0.001	1.364	1.098-1.693	0.005
Surgical approach			0.396
Open	1.000
Laparoscopic	0.788	0.545-1.140	0.206
Robotic	0.730	0.234-2.276	0.587
Tumor location			0.023			0.058
Cardia and fundus of stomach	1.000			1.000
Gastric body	1.257	0.965-1.638	0.090	1.386	1.056-1.818	0.019
Pylorus	0.825	0.639-1.066	0.141	1.176	0.899-1.537	0.237
Tumor site			0.419
Lesser curvature side	1.000
Greater curvature side	1.242	0.891-1.732	0.201
Anterior wall	0.638	0.340-1.200	0.164
Posterior wall	1.004	0.587-1.719	0.987
Total stomach	1.107	0.570-2.151	0.764
Pathological type	0.834	0.505-1.378	0.479
Differentiation degree			0.202
Poorly differentiated	1.000
Moderately differentiated	0.800	0.627-1.022	0.074
Highly differentiated	0.000	0.000-2.60E+107	0.933
Tumor size	2.345	1.896-2.901	0.000	1.283	1.014-1.623	0.038
T stage			0.000			0.000
T1	1.000			1.000
T2	2.176	1.057-4.480	0.035	1.699	0.820-3.523	0.154
T3	4.776	2.514-9.075	0.000	2.468	1.261-4.830	0.008
T4	7.137	4.092-12.449	0.000	3.480	1.924-6.296	0.000
N stage			0.000			0.000
N0	1.000			1.000
N1	2.116	1.474-3.037	0.000	1.508	1.040-2.186	0.030
N2	3.214	2.321-4.449	0.000	2.064	1.470-2.897	0.000
N3	4.777	3.564-6.403	0.000	2.491	1.805-3.440	0.000
Systemic inflammation response index-platelet-to-lymphocyte ratio			0.000			0.013
0	1.000			1.000
1	1.421	1.040-1.943	0.028	1.444	1.051-1.982	0.023
2	2.297	1.691-3.120	0.000	1.759	1.204-2.571	0.004
Neutrophil-to-lymphocyte ratio	1.463	1.153-1.857	0.002	0.912	0.677-1.229	0.545
Systemic immune-inflammation index	1.669	1.343-2.074	0.000	1.037	0.750-1.434	0.825
Carcinoembryonic antigen	2.512	2.030-3.109	0.000	2.049	1.643-2.556	0.000